Andere talen Lupin Limited NSE India S.E.

Aandelen

LUPIN

INE326A01037

Vertraagde tijd NSE India S.E. Andere beurzen 06:18:56 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.590 ^INR	+0,39%		-4,01%	+20,06%

09/05	LUPIN LIMITED : Nomura herhaalt koopadvies	ZM
09/05	Lupin Limited kondigt bestuursbenoemingen aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lupin : May 9, 2024 Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors	09/05
Lupin Limited Announces Board Appointments	09/05
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	07/05
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	06/05
Lupin : May 6, 2024 Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	06/05
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	06/05
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06/05
Lupin : May 3, 2024 Lupin Launches Rymti® Biosimilar Etanercept in Canada	03/05
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	30/04
Lupin : April 25, 2024 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%	25/04
Lupin : April 25, 2024 Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO	25/04
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	24/04
Lupin : April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility	24/04
Lupin : April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States	22/04
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	22/04
Lupin Launches Mirabegron Extended-Release Tablets in US	22/04
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	20/04
Lupin : April 12, 2024 U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations	12/04
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	12/04
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	10/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lupin Limited NSE India S.E.

Aandelen

LUPIN

INE326A01037

Andere talen

Filters